Introduction
============

Canine otitis externa, an acute or chronic inflammation of the external ear canal epithelium, is a common presentation in small animal practice. Although not life-threatening, the therapeutic intervention can be challenging and frustrating because several perpetuating factors frequently prevent healing. Micro-organisms are common secondary factors that can maintain and worsen the disease process. *Staphylococcus* spp. are among the most common bacterial pathogens isolated from dogs with otitis externa,[@b1] other significant bacteria are *Pseudomonas aeruginosa*,*Escherichia coli* and *Proteus mirabilis*.

Antimicrobial therapy using polymyxin B and miconazole has been proved to be effective against the main bacterial pathogens associated with otitis externa in clinical studies.[@b2]--[@b5] While miconazole kills fungi and some Gram-positive bacteria,[@b6] polymyxin B has antifungal properties[@b7] and antibacterial activity against a wide variety of Gram-negative and, to a lesser extent, Gram-positive microbes.[@b8] Most importantly, this agent is effective against various strains of antibiotic-resistant bacteria.[@b9]

The polymyxins are cationic polypeptides that target and disrupt the bacterial cell membrane. This causes an increase in the permeability of the cell envelope, leakage of cell contents and, subsequently, cell death. When combined with various drugs, polymyxins have a potential for enhanced activity, which is related to their ability to increase the penetration of other agents into the cell.[@b10]

In the past, several studies demonstrated synergistic antimicrobial *in vitro* activity when polymyxins are combined with different antimicrobial agents.[@b11],[@b12] By combining polymyxin B with miconazole, synergism was reported against *Candida albicans*,[@b13] against strains of *Staphylococcus aureus* and *E. coli*[@b14] and against type strains of *E*. *coli*,*P. aeruginosa* and *Malassezia pachydermatis*.[@b14],[@b15]

So far, the incidence of resistance to miconazole has been low in clinical isolates[@b16] or in laboratory experiments.[@b17] Resistance to polymyxin B, largely due to lipopolysaccharide modifications,[@b11],[@b18] was either low[@b19] or could not be detected at all in canine and feline bacterial strains.[@b20] In human isolates of *P. aeruginosa*, resistance to polymyxins was reported to be \<5% for specific subpopulations within a species.[@b11],[@b21] Inconsistent with these reports, in distinct geographical regions of the world higher prevalence of resistance has been reported.[@b22] Recent data from the SENTRY Antimicrobial Surveillance Program 2006--2009 described excellent *in vitro* activity of polymyxins against a worldwide collection of Gram-negative pathogens, with a trend towards greater resistance in Asia-Pacific and Latin-America regions.[@b23]

The objective of the present study was an analysis of synergism of a combination of polymyxin B and miconazole *in vitro* not only on type strains[@b15] but also on clinical strains of *Staphylococcus pseudintermedius*,*P. aeruginosa*,*E. coli* and *P. mirabilis* associated with canine otitis externa. Equal molar concentrations of both drugs were combined to approach the mode of action. A second objective was a survey of the susceptibility of these bacterial species in different European countries.

Materials and methods
=====================

Bacterial strains
-----------------

For broad and representative sampling, bacterial strains were taken from different regions of Germany, France and Italy. The bacteria were sampled in 2009 and 2010 by different laboratories from cases of acute canine otitis externa using regular submissions by veterinary practices, clinics or veterinary faculties for identification of bacterial genus and species. The veterinary practices and faculties made the diagnosis of acute otitis externa (abrupt onset of signs and symptoms). They collected samples from one ear of each dog with sterile cotton swabs (various brands), which were sent daily to resident laboratories (Laboklin GmbH & Co. KG, Bad Kissingen, Germany; Vébiotel, Arcueil, Cedex, France; Department of Animal Production, Epidemiology and Ecology, School of Veterinary Medicine of Turin, Italy).

For analysis of susceptibility and synergy testing, bacterial samples were transferred to a single laboratory. In this study, we included isolates of *E. coli* (haemolytic and nonhaemolytic) originating from Germany and France (*n* = 17); samples from Italy did not contain *E. coli*. Isolates of *P. aeruginosa* (*n* = 24), *P. mirabilis* (*n* = 24) and *S. pseudintermedius* (formerly *S. intermedius*;[@b24] *n* = 25) were investigated from Germany, France and Italy. Regardless of regional aspects, meticillin-resistant *S. pseudintermedius* (MRSP) strains from The Netherlands (*n* = 5) were included in this study to compare their susceptibility to polymyxin B and miconazole with that of strains from Germany, France and Italy. The strains were sampled from dogs suffering from acute otitis externa.

For the bacterial species investigated in this study, type strains ATCC 25922, ATCC 27853, ATCC 29663 and ATCC 29906 served as quality controls (QC strain).

For certainty, we repeated bacterial characterization. We plated the isolates on trypticase soy agar and cetrimide agar (heipha GmbH, Eppelheim, Germany). Purified isolates were identified from their appearance on solid medium, cell morphology, odour, pigment production, Gram properties, haemolysis and catalase and oxidase reaction. Additional biochemical species identification was achieved by applying API Staph ID 32 for *Staphylococcus* spp., API 20 NE for non-enteric Gram-negative rods and API 20 E for enteric bacteria (BioMérieux, Nürtingen, Germany).

Antimicrobial agents
--------------------

Polymyxin B sulfate (Sigma-Aldrich, Taufkirchen, Germany) was dissolved in deionized water. Miconazole nitrate salt (Sigma-Aldrich) was dissolved in a solution containing 1.88 mol/L polyethyleneglycol 400 and 5.43 mol/L ethanol. Both antibiotic solutions were filter sterilized (Minisart nylon filter, pore size 0.2 μm; Sartorius, Göttingen, Germany) prior to use.

For quality control of the antimicrobial agents, aliquots of the antibiotic stock solutions of polymyxin B sulfate and miconazole nitrate were retained and analysed for content of active substance by high-pressure liquid chromatography (HPLC) using the Merck/Hitachi LaChrom 2 HPLC-System with UV-Detector and Software Merck/Hitachi D-7000 HSM HPLC System Manager Software on the first day and 6 weeks after preparation. In the polymyxin B sulfate solution, the content decreased by 14.41%, and in the miconazole nitrate solution there was a decrease of 9.26% after 6 weeks.

Additionally, the sterile filtering process was controlled for potential losses of antimicrobial agents. Solutions of polymyxin B sulfate and miconazole nitrate were filtered using either Minisart Plus syringe filter (cellulose acetate membrane with GF prefilter; Sartorius Stedim Biotech GmbH, Göttingen, Germany) or Minisart NML syringe filter \[surfactant-free cellulose acetate (SFCA) membrane; Sartorius Stedim Biotech GmbH\]. There was no detectable loss of polymyxin B or miconazole following sterile filtration with Minisart Plus or Minisart NML filters. We concluded that the antibiotics did not bind to the surface of the filters.

The procedures and the detailed results of these parallel experiments are reported in ECON report numbers 1022-08 and 1022-09 (M. Voget, M. Armbruster, unpublished results).

Susceptibility tests
--------------------

Susceptibility to antimicrobial agents was assessed using the broth microdilution method according to recommendations of the Clinical and Laboratory Standards Institute, protocol M7-A8.[@b25] The minimal inhibitory concentration (MIC) end-points were evaluated visually, and the results were verified photometrically at an optical density (OD) of 490 nm. The MIC was read as the lowest concentration of antimicrobial substance which inhibited visible growth. Following MIC determination, subcultures onto Müller-Hinton agar plates (Sifin, Berlin, Germany), free of antibacterial substances, were made from wells that failed to show macroscopic growth and reincubated for an additional 18--24 h to determine the minimal bactericidal concentration (MBC). The MBC was read as the lowest concentration of antimicrobial substance which reduced bacterial counts by 99.9% (3-log~10~ reduction in colony-forming units). Bactericidal activity was interpreted as a ratio of MBC to MIC ≤4.

Synergy trials were performed as chequerboard interactions in microtitre plates. Bacteria were added to a twofold serial dilution of a single antibiotic agent or in combination with an identical dilution of the other tested antibiotic agent. Concentrations tested in combination consisted of equal molar concentrations of polymyxin B and miconazole. They varied from 275.0 mg/L polymyxin B combined with 93.75 mg/L miconazole (corresponding to 2.25 × 10^−4^ mol/L of each drug) to 1.68 × 10^−2 ^mg/L polymyxin B combined with 5.72 × 10^−3 ^mg/L miconazole (corresponding to 1.35 × 10^−8^ mol/mL of each drug). One negative (no bacteria) and two positive controls (no antibiotic, and no antibiotic but solvent of miconazole solution) were used on each plate.

Statistical analysis
--------------------

The fractional inhibitory concentration index (FICI) was calculated according to the equation FICI = MIC(A~B~)/MIC(A) + MIC(B~A~)/MIC(B) where MIC(A) and MIC(B) denote the MIC of drug A and the MIC of drug B alone, MIC(A~B~) and MIC(B~A~) are corresponding MICs of drug A in the presence of drug B and *vice versa*. An FICI ≤0.5 was interpreted as synergy, and a FICI \> 0.5−4 was interpreted as no interaction of both drugs.[@b26]

The MICs and calculated FICIs were summarized descriptively by the sample size *n*, the mode, the median, the interquartile range (IQR) and the minimal and maximal values. The median enables a description of the central tendency largely unaffected by outliers, whereas the mode facilitates the recognition of samples having more than one maximum. The Kruskal--Wallis rank sum test was used to study whether FICI calculated from samples taken in the different countries originate from the same distribution. Subsequently, one-sided Wilcoxon signed-rank tests were performed to test whether the FICIs were smaller than 1.0 and 0.5, respectively. In all hypothesis tests, *P* \< 0.05 was considered significant. The *P*-values are labelled *p*~c~ for the test of grouping by country, and *p*~\<1.0~ and *p*~\<0.5~ for the test of upper limits of the FICI. All calculations were carried out with the R-package for statistical computing (R Foundation for Statistical Computing, Vienna, Austria).[@b27]

Results
=======

Geographical variations
-----------------------

The geographical variation of MIC and FICI was studied in samples taken in Germany, France and Italy. For polymyxin B, there was no evidence of a geographical variation of MIC in *E. coli* (*p*~c~, *P*-value for test of MIC grouping by country = 0.314), *P. aeruginosa* (*p*~c~ = 0.420) and *S. pseudintermedius* (*p*~c~ = 0.496). Likewise, geographical region was not a relevant factor for the MIC of miconazole in *S. pseudintermedius* (*p*~c~ = 0.775). Furthermore, we found no significant geographical variation of FICI for all the aforementioned strains (Tables[3](#tbl3){ref-type="table"}). Hence, MIC and FICI data were pooled, and the results of the combined data set are presented below.

###### 

*In vitro* activity of polymyxin B and miconazole against *Escherichia coli* strains

                                        QC strain   Germany      France       Total
  ------------------------------------- ----------- ------------ ------------ --------------
  *n*                                               12           5            17
  MIC for polymyxin B (μg/mL)                                                 
   Mode                                 0.27        0.27         ---          0.27
   Median                                           0.27         0.54         0.27
   IQR                                              0.27--0.27   1.07--0.27   0.54--0.27
   Minimum                                          0.13         0.13         0.13
   Maximum                                          1.07         4.30         4.30
  FICI for polymyxin B and miconazole                                         
   Mode                                 0.25        0.25         0.25, 0.50   0.25
   Median                                           0.25         0.25         0.25
   IQR                                              0.50--0.25   0.50--0.25   0.50--0.25
   Minimum                                          0.06         0.06         0.06
   Maximum                                          0.50         0.50         0.50
  *P*-values                                                                  
   *p*~c~                                                                     0.955
   *p*~\<1.0~                                                                 1.3 × 10^−4^
   *p*~\<0.5~                                                                 0.001

Abbreviations: FICI, fractional inhibitory concentration index; IQR, interquartile range; MIC, minimal inhibitory concentration; *n*, number of isolates; *p*~c~, *P*-value for test of FICI grouping by country; *p*~\<1.0~ and *p*~\<0.5~, *P*-values for tests of FICI \< 1.0 and FICI \< 0.5; and QC, quality control.

###### 

*In vitro* activity of polymyxin B and miconazole against *Pseudomonas aeruginosa* strains

                                        QC strain   Germany      France       Italy        Total
  ------------------------------------- ----------- ------------ ------------ ------------ --------------
  MIC for polymyxin B (μg/mL)                                                              
   *n*                                              8            8            8            24
   Mode                                 0.27        0.27         0.54         0.54         0.54
   Median                                           0.54         0.54         0.54         0.54
   IQR                                              1.07--0.27   0.54--0.27   1.07--0.54   1.07--0.27
   Minimum                                          0.27         0.27         0.27         0.27
   Maximum                                          \>275        1.07         1.07         \>275
  FICI for polymyxin B and miconazole                                                      
   *n*                                              6            8            8            22
   Mode                                 0.50        0.50         0.25         0.50         0.50
   Median                                           0.50         0.25         0.50         0.50
   IQR                                              0.50--0.50   0.50--0.25   0.63--0.44   0.50--0.25
   Minimum                                          0.13         0.13         0.25         0.13
   Maximum                                          0.50         1.00         1.00         1.00
  *P*-values                                                                               
   *p*~c~                                                                                  0.200
   *p*~\<1.0~                                                                              4.7 × 10^−5^
   *p*~\<0.5~                                                                              0.348

Abbreviations are as for Table [1](#tbl1){ref-type="table"}.

###### 

*In vitro* activity of polymyxin B and miconazole against *Staphylococcus pseudintermedius* strains

                                        QC strain   Germany       France       Italy         Total
  ------------------------------------- ----------- ------------- ------------ ------------- -------------
  *n*                                               8             8            9             25
  MIC for polymyxin B (μg/mL)                                                                
   Mode                                 8.59        17.19         8.59         4.30, \>275   8.59
   Median                                           17.19         8.59         17.19         8.59
   IQR                                              17.19--8.59   8.59--4.30   \>275--4.30   17.19--8.59
   Minimum                                          8.59          4.30         4.30          4.30
   Maximum                                          34.38         34.38        \>275         \>275
  MIC for miconazole (μg/mL)                                                                 
   Mode                                 2.93        1.47          1.47         1.47          1.47
   Median                                           1.47          1.47         1.47          1.47
   IQR                                              2.93--1.47    1.47--1.47   2.93 -1.47    2.93--1.47
   Minimum                                          1.47          0.73         0.73          0.73
   Maximum                                          5.86          5.86         11.72         11.72
  FICI for polymyxin B and miconazole                                                        
   Mode                                 1.00        0.50          1.00         0.75, 1.25    1.25
   Median                                           0.59          1.00         1.00          1.00
   IQR                                              1.06--0.55    1.47--1.31   1.25--0.75    1.25--0.56
   Minimum                                          0.50          0.56         0.83          0.83
   Maximum                                          1.50          1.50         2.06          2.06
  *P*-values                                                                                 
   *p*~c~                                                                                    0.288
   *p*~\<1.0~                                                                                0.348
   *p*~\<0.5~                                                                                1.000

Abbreviations are as for Table [1](#tbl1){ref-type="table"}.

###### 

*In vitro* activity of polymyxin B and miconazole against meticillin-resistant *Staphylococcus pseudintermedius* (MRSP) strains

                                        MRSP
  ------------------------------------- --------------
  *n*                                   5
  MIC for polymyxin B (μg/mL)           
   Mode                                 17.19
   Median                               17.19
   IQR                                  17.19--17.19
   Minimum                              8.59
   Maximum                              17.19
  MIC for miconazole (μg/mL)            
   Mode                                 5.86
   Median                               2.93
   IQR                                  5.86--2.93
   Minimum                              1.47
   Maximum                              5.86
  FICI for polymyxin B and miconazole   
   Mode                                 0.75
   Median                               0.75
   IQR                                  0.75--0.75
   Minimum                              0.50
   Maximum                              1.25

Abbreviations are as for Table [1](#tbl1){ref-type="table"}.

Minimal inhibitory concentrations
---------------------------------

Against *E. coli* strains from Germany and France, MICs of polymyxin B ranged from 0.13 to 4.30 μg/mL; the mode and median MIC of the sample pooled for statistics were 0.27 μg/mL (Table [1](#tbl1){ref-type="table"}). There was no inhibition of bacterial growth when miconazole was applied alone.

Against *P. aeruginosa* strains from Germany, France and Italy, MICs of polymyxin B ranged from 0.27 to 1.07 μg/mL. In two strains of *P. aeruginosa* from Germany, there was no inhibition by polymyxin B at the maximal experimentally accessible concentration of 275 μg/mL (Table [2](#tbl2){ref-type="table"}). The mode and median MIC of polymyxin B was 0.54 μg/mL (Table [2](#tbl2){ref-type="table"}). Miconazole when given alone did not inhibit bacterial growth.

Against *S. pseudintermedius* strains from Germany, France and Italy, MICs of polymyxin B ranged from 4.30 to 34.38 μg/mL. The mode and median MIC of polymyxin B were 8.59 and 17.19 μg/mL, respectively. Three strains from Italy were not inhibited by the maximal experimentally accessible concentration of 275 μg/mL polymyxin B (Table [3](#tbl3){ref-type="table"}). The finding that three strains from Italy were not inhibited at the highest concentration is reflected by the bimodal MIC with most frequent observations of 4.30 and \> 275 μg/mL. All MRSP strains were inhibited by polymyxin B at concentrations of 8.59--17.19 μg/mL (Table [4](#tbl4){ref-type="table"}).

The MICs of miconazole against the *Staphylococcus* strains from all countries were in the range of 0.73--11.72 μg/mL, while the MRSP strains ranged from 1.47 to 5.86 μg/mL. In the pooled *S. pseudintermedius* samples, the mode and median MIC values of miconazole were 1.47 μg/mL. In our MRSP samples, we found the most frequent inhibition at 5.86 μg/mL, whereas the median inhibition of the samples was 2.93 μg/mL. None of the strains of *P. mirabilis* was inhibited by polymyxin B or by miconazole at the concentrations tested.

Minimal bactericidal concentrations
-----------------------------------

Susceptibility to polymyxin B and miconazole was evaluated by MBC determination and calculation of the MBC/MIC ratio (Fig. S1 in Supplementary material). For *E. coli*, 100% of the clinical strains from Germany and France had an MBC/MIC ratio of 1. For 46% of the clinical *P. aeruginosa* strains from three countries, the MBC/MIC ratio was also 1. Another 42% of these strains had a MBC/MIC ratio of 2, 4% of the strains had a MBC/MIC ratio of 8, and 8% of the strains were not inhibited by polymyxin B, hence the MBC/MIC ratio was not calculable. The MICs for the Gram-negative QC strains conformed to published values.[@b28] For polymyxin B, 67% of the clinical strains of *S. pseudintermedius* and all MRSP strains showed an MBC/MIC ratio of 1. Furthermore, 13, 7, and 3% of these strains showed MBC/MIC ratios of 2, 4 and 8, respectively, while 10% were not inhibited by polymyxin B. Miconazole had bactericidal activity against all isolates of *Staphylococcus* too. The MBC/MIC ratio was 1 for 50% of the clinical *S. pseudintermedius* strains, and for the MRSP strains, 2 for 40% and 4 for 10% of the strains (Fig. S1 in Supplementary material). The combination of both drugs had no impact on the MBC/MIC ratios. The results from MIC and MBC testing indicated that polymyxin B exhibited bactericidal activity against most strains tested, while miconazole was bactericidal solely against the Gram-positive isolates.

Synergism
---------

For the *E. coli* samples from Germany and France pooled for statistical analysis, the FICI was determined to be 0.25. The minimal and maximal values were 0.06 and 0.50. The FICI was significantly smaller than 0.5 (*p*~\<0.5~ = 0.001). Consequently, the criteria for synergy were met.

The minimal and maximal FICI values for *P. aeruginosa* were 0.13 and 1.00, respectively. There was evidence for FICI \< 1 (*p*~\<1.0~ = 4.7 × 10^−5^). Although it could not be shown that FICI \< 0.5 (*p*~\<0.5~ = 0.348), the mode and median FICI were exactly 0.5, which indicates a synergistic interaction of both drugs.

For *S. pseudintermedius*, the FICI mode of 1.25 is somewhat higher than the median of 1.00. The minimal and maximal FICI were 0.38 and 2.06, respectively. Due to the variation of the data, there was not sufficient evidence to prove that FICI \< 1 (*p*~\<1.0~ = 0.348) for the strains from Germany, France and Italy. Thus, interaction between both drugs if applied against *S. pseudintermedius* isolates could not be demonstrated. For the MRSP strains, both location parameters, the mode and median were 0.75.

Discussion
==========

This study aimed to investigate whether a synergistic effect of polymyxin B with miconazole was exerted on clinical strains from three different countries in Europe. To produce objective data for the prudent application of polymyxin B and miconazole, the present study evaluated the efficacy of these drugs alone and in combination against clinical isolates of *E. coli*,*P. aeruginosa*,*S. pseudintermedius* and *P. mirabilis* using MIC, MBC and FICI determination.

Our data revealed no evidence of different sensitivity to polymyxin B and miconazole of clinical strains from cases of canine otitis externa in the European countries France, Germany and Italy in terms of MIC and FICI. Thus, the results were presented in a joint statistical analysis. In addition, our investigation confirms a synergistic activity of polymyxin B combined with miconazole against strains of *E. coli* and *P. aeruginosa*. Although the *S. pseudintermedius* strains on average did not fulfil the rigorous criteria for synergism, there was a substantial reduction in MIC if both antibiotic agents were acting together.

Clinical isolates of *E. coli* and *P. aeruginosa* showed a high level of susceptibility to polymyxin B, with MICs being consistently low. In general, *Staphylococcus* spp. are regarded as poor targets for polymyxins, with high MIC values ranging from 8 to 64 μg/mL.[@b9],[@b15],[@b29] Our results confirm these data, in that the MIC values for the *S. pseudintermedius* strains from all countries were in the range of 4.3--34.4 μg/mL and for the MRSP strains in the range of 8.6--17.19 μg/mL. In contrast to these data, in a recent study[@b30] MIC values for MRSP strains were remarkably low, ranging from 0.25 to 4 μg/mL, while for MRSA strains the MIC values were significantly higher and ranged from 8 to 64 μg/mL.

It is noteworthy that miconazole was able to kill the *S. pseudintermedius* isolates, and the MICs from 0.73 to 11.72 μg/mL are extensively consistent with data from previous *in vitro* studies.[@b15] Both polymyxin B and miconazole alone and in combination could inhibit the MRSP strains and exerted strong bactericidal activity as well. For the majority of strains tested, the MBC did not exceed four times the MIC, thus bactericidal activity was confirmed. This conforms to the known mode of action of polymyxins and anticipates a rapid killing of the target pathogens.

The bactericidal activity of polymyxin B and miconazole is of clinical importance. While many infections respond equally well to bacteriostatic agents as to bactericidal ones,[@b31] in theory the killing of bacteria should produce a more rapid resolution of infection along with an improved clinical outcome,[@b32] and the faster elimination of bacterial pathogens should also minimize the likelihood of the emergence of resistance and spread of infection. However, *in vitro* testing methods that are used to categorize antibacterial agents as bactericidal may not duplicate the conditions found *in vivo*. For instance, polymyxin B is known to be inactivated in purulent exudates.[@b33] Thus, clinicians must consider drug concentrations at the site of infection or local factors that impair drug activity, such as low pH, the presence of pus or high protein concentration, to determine the optimal treatment.

None of the strains except *Proteus* exhibited resistance to miconazole, but polymyxin B was not active against two clinical isolates of *P. aeruginosa* from Germany and three *Staphylococcus* strains from Italy. This might indicate waning susceptibility to polymyxins in different European countries. A progressive increase in MICs of polymyxins was assigned to prolonged treatment with polymyxins;[@b34],[@b35] thus, data from microbiological field studies may point to the usage of polymyxins in certain regions.

The clinical isolates of *P. mirabilis* revealed resistance to both drugs if given alone. Unexpectedly, resistance is maintained if both drugs are given in combination. Intrinsic resistance of *Proteus* species to polymyxins is established and based on changes in lipid A. The isolates from our study that remained unaffected by polymyxin may provide a contribution to our understanding of how both antibacterial agents co-operate to damage bacteria. In Gram-negative microbes, the synergistic action of polymyxin and miconazole is supposed to originate from the ability of polymyxin to stimulate the uptake of the hydrophobic miconazole to the intracellular space,[@b36] where it increases the level of reactive oxygen species.[@b37] In bacteria resistant to polymyxin B, the drug has no access to the cell membrane and cannot disrupt it; thus, miconazole fails to penetrate into the cells and leaves those bacteria unaffected. In Gram-positive bacteria, the cell membrane is not exposed, hence polymyxin B has little activity against them. In these microbes, the synergistic interaction of polymyxin B and miconazole may result predominantly from miconazole that impairs the cell wall and alters its permeability, which then allows polymyxin to gain access through the cell wall to disrupt the cytoplasmic membrane.

To explore the mechanism of action and potential targets for the antimicrobial agents, our study presents systematically increasing concentrations of polymyxin B and miconazole either alone or combined in equal molarity. Results from this setting were compared with data from previous studies where identical masses of the antibiotic substances were combined.[@b15] Both approaches yielded matching results, because the antibacterial agents acted synergistically against the Gram-negative *E. coli* and *P. aeruginosa* and showed on average no interaction against *S. pseudintermedius* strains. Thus, the impact of both agents on the bacterial cell is a monomolar reaction, as one mole of polymyxin B combined with one mole of miconazole is sufficient to produce these results.

Synergism was addressed by means of FICI. The mode was 0.25, 0.50, 1.25 and 0.75 for *E. coli*,*P. aeruginosa*,*S. pseudintermedius* and the MRSP strains, respectively. These results agree with the median except for the *Staphylococcus* strains from Germany, France and Italy (1.00). In general, there is a close correspondence between the median, separating the higher and the lower half of the sample, and the mode, the most frequent value. Both are used to describe the central tendency of FICI from a different perspective. Accordingly, in a common interpretation, 'no interaction' corresponds to FICI = 1, synergism corresponds to FICI \< 1, and for antagonism FICI is \>1. However, due to inherent inaccuracies of the experimental method, a more rigorous limit of FICI ≤ 0.5 for synergism and FICI \> 4 for antagonism is required by the editorial policies of many journals.[@b26],[@b38] More recently, symmetrical limits of 0.5 and 2 have been proposed for 'no interaction'.[@b39] Further minor deviations of the FICI from 1 do not appear to be relevant practically. Thus, we tested whether the experimentally determined FICIs are \<1.0 and \<0.5. For *E. coli*, there is high evidence of synergism, in that the FICI = 0.25 is significantly smaller than the rigorous limit of 0.5. For *P. aeruginosa*, the FICI determined from pooled data is clearly smaller than 1, but not lower than the rigorous limit. Instead, the FICI estimated from samples from three countries is located exactly at the upper limit of 0.5 for synergism. For *S. pseudintermedius* strains, the median of FICI is 1.0, and the IQR of 0.56--1.25 suggests no interaction. This also holds true for the MRSP strains, although the median FICI of 0.75 is lower. While most strains were rendered more susceptible when both drugs were used in combination, a definite synergistic effect for all strains was missing. With this bacterial species, *in vitro* synergy may be strain dependent, because for some *S. pseudintermedius* isolates a boosted effect was obvious while for others there was no interaction.

The combination of both drugs has the potential for synergistic action not only *in vitro*, but it may be also of clinical relevance. Polymyxins produce concentration-dependent killing, with an initial kill followed by regrowth.[@b11] In the light of the routine occurrence of regrowth, combination therapy may prove to be more efficacious, because this strategy suppresses bacterial regrowth at subinhibitory concentration and/or avoids the appearance of heteroresistant strains. From *in vitro* susceptibility testing of polymyxin B combined with miconazole, a synergistic effect against the Gram-negative bacterial isolates was evident. If we consider topical remedies for combating veterinary otic bacterial pathogens, they provide antimicrobial drugs in excess. With preparations for local administration, up to 1000 times the MIC values for the bacteria tested are present at the site of application, and persistence of miconazole in the external ear canal for 10 days was shown at concentrations exceeding the MIC values that inhibit 90% of bacterial isolates.[@b40] These high local concentrations exert a strong killing potential and minimize the risk of microbial resistance.

Overall, our results revealed that clinical strains from three European countries show a similar *in vitro* susceptibility to polymyxin B and miconazole. Antibiotic synergism of polymyxin B and miconazole against the Gram-negative *E. coli* and *P. aeruginosa* strains was demonstrated, and both agents, when applied in combination, showed a substantial bactericidal activity against almost all of the strains tested. In search of effective chemotherapeutic approaches for treating otitis externa, combination therapy using polymyxin B and miconazole can be of potent therapeutic value against the pathogens commonly associated with this disease. The *in vitro* synergy of polymyxin B and miconazole may result in better treatment results for otitis externa associated with Gram-negative bacterial infections.
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MBC/MIC ratios of polymyxin B or miconazole for bacterial isolates from all countries.
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